美股市場個股詳情

ORGO Organogenesis

添加自選

2.445
-0.045-1.81%

交易中 05/06 09:49 (美東)

3.24億總市值61.13市盈率TTM

Organogenesis股票討論區

登錄發表評論

Stock Region

05/03 02:26

Therapeutics Company Achieves Promising Clinical Trial Results For Knee Osteoarthritis Therapy

The implications of ReNu’s success extend far beyond symptom management.
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...

Jaguar8

05/02 19:04

$Organogenesis(ORGO.US)$
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...

beachlover

04/04 23:22

$Organogenesis(ORGO.US)$ 🔥HUBC🔥

Moomoo AI

03/04 22:06

Despite poor earnings, the high P/E ratio indicates investors anticipate strong future growth, justifying a higher stock price. Unless earnings significantly deteriorate, the share price should remain strong.

Organogenesis Holdings Inc.'s (NASDAQ:ORGO) P/E Is On The Mark

Moomoo AI

01/14 20:42

Albert Erani's recent sale of Organogenesis Holdings shares, the largest insider sale in the past year, raises concerns despite the high sale price. The absence of insider buying and presence of selling suggest a cautious outlook, despite high insider ownership.

Have Insiders Sold Organogenesis Holdings Shares Recently?

StaNnnn

2023/12/15 12:14

Looking Forward... It is a good setup

$Organogenesis(ORGO.US)$

GAME_DAY

2023/09/29 01:03

Current watch ⚡️

$歐朋公司(OPRA.US)$ $大健雲倉(GCT.US)$ $Sunrun(RUN.US)$ $車車科技(CCG.US)$ $Lululemon Athletica(LULU.US)$ $Aytu BioPharma(AYTU.US)$ $Organogenesis(ORGO.US)$ $Genasys(GNSS.US)$ $Bionomics(BNOX.US)$ $Sirius XM(SIRI.US)$

逍遥投资派

2023/05/26 23:08

$Organogenesis(ORGO.US)$營收5年來總體高速增長，平均增速爲17.9%，2022年略微萎縮3.5%，營業利潤2020年扭虧，2021年達到0.72億的高點，2022年大幅下滑69%，淨利潤也類似，2021年達到0.94億的高點，2022年大幅下滑83.5%到0.155億。
利潤表顯示2022年營收雖然下滑，但是營業費用卻繼續高速增長造成了營業利潤的大幅下滑。利息費用佔營業利潤的9%，負擔不算太重。
2023Q1營收增長10.8%，營業利潤進入虧損區間，還是由於營業費用增加過快造成的，看起來公司費用控制能力非常差勁。
5年來資產負債率從71.3%下降到40.9%。
資產負債率顯示應收和存貨比例和增速都比較正常，長期借款0.66億，佔淨資產的25%，槓桿率正常。
5年來現金流經營淨額累計還是淨流出狀態，還有大筆的現金流投資淨流出，沒有產生股東盈餘。
目前31.8倍市盈率，34.6倍市盈率TTM，可以再觀察幾份財報，着重看營業費用佔比情況是否有所改善再做判斷。

已翻譯